Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | Chief Medical Officer | May 16, 2018 | May 18, 2018 |
| Inozyme Pharma, Inc.INZY · Entity 77717 | SVP, CMO | January 13, 2021 | January 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eloxx Pharmaceuticals, Inc.
Report date May 16, 2018 · Filed May 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,725 |
Reported balance
After 2018-05-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-05-16 · Grant · Acquired 33,000 · Balance 137,725 F1: Represents a restricted stock unit ("RSU") award that will vest one quarter (1/4) of the RSUs on May 16, 2019 (the "Initial RSU Vesting Date") and one sixteenth (1/16) of the RSUs shall vest on each successive quarterly anniversary of the Initial RSU Vesting Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award that will vest one quarter (1/4) of the RSUs on May 16, 2019 (the "Initial RSU Vesting Date") and one sixteenth (1/16) of the RSUs shall vest on each successive quarterly anniversary of the Initial RSU Vesting Date.
Inozyme Pharma, Inc.
Report date January 13, 2021 · Filed January 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.77 · Expires 2030-04-22 | Direct | 36,074 |
Reported balance
After 2021-01-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-13 · Grant · Acquired 36,074 · Balance 36,074 F1: This option was granted on April 23, 2020, with vesting subject to the satisfaction of performance based vesting criteria. The performance based vesting criteria were satisfied on January 13, 2021 and the shares underlying the option vest in equal monthly installments from April 23, 2020 through April 23, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on April 23, 2020, with vesting subject to the satisfaction of performance based vesting criteria. The performance based vesting criteria were satisfied on January 13, 2021 and the shares underlying the option vest in equal monthly installments from April 23, 2020 through April 23, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 13, 2021 Filed Jan 14, 2021 16:17 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (Right to buy) · Derivative | 36,074 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001209191-21-003596 · doc4.xml · derivative · entry 1 Huertas Pedro · CIK 0001389517 · SVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,074 Underlying: Common Stock · 36,074 shares Expires 2030-04-22 F1 · derivative.exercise_date: This option was granted on April 23, 2020, with vesting subject to the satisfaction of performance based vesting criteria. The performance based vesting criteria were satisfied on January 13, 2021 and the shares underlying the option vest in equal monthly installments from April 23, 2020 through April 23, 2024. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 16:54 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 43,951 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020404 · doc4.xml · derivative · entry 1 Huertas Pedro · CIK 0001389517 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,951 Underlying: Common Stock · 43,951 shares Expires 2030-07-22 F1 · derivative.exercise_date: The option was granted on July 23, 2020. The shares underlying the option are scheduled to vest in equal monthly installments from July 23, 2020 through July 23, 2024. Read SEC document |
| May 16, 2018 Filed May 18, 2018 12:05 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031252 · doc4.xml · nonDerivative · entry 1 Huertas Pedro · CIK 0001389517 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,725 F1 · security: Represents a restricted stock unit ("RSU") award that will vest one quarter (1/4) of the RSUs on May 16, 2019 (the "Initial RSU Vesting Date") and one sixteenth (1/16) of the RSUs shall vest on each successive quarterly anniversary of the Initial RSU Vesting Date. F1 · shares: Represents a restricted stock unit ("RSU") award that will vest one quarter (1/4) of the RSUs on May 16, 2019 (the "Initial RSU Vesting Date") and one sixteenth (1/16) of the RSUs shall vest on each successive quarterly anniversary of the Initial RSU Vesting Date. Read SEC document |
| May 11, 2018 Filed May 11, 2018 20:05 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantCommon Stock | 104,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-029518 · doc4.xml · nonDerivative · entry 1 Huertas Pedro · CIK 0001389517 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,725 F1 · security: Represents a restricted stock unit ("RSU") award that will vest one quarter (1/4) of the RSUs on March 12, 2019 (the "Initial RSU Vesting Date") and one sixteenth (1/16) of the RSUs shall vest on each successive quarterly anniversary of the Initial RSU Vesting Date. F1 · shares: Represents a restricted stock unit ("RSU") award that will vest one quarter (1/4) of the RSUs on March 12, 2019 (the "Initial RSU Vesting Date") and one sixteenth (1/16) of the RSUs shall vest on each successive quarterly anniversary of the Initial RSU Vesting Date. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:05 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantEmployee Stock Option (Right to Buy) · Derivative | 104,725 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001209191-18-029518 · doc4.xml · derivative · entry 2 Huertas Pedro · CIK 0001389517 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,725 Underlying: Common Stock · 104,725 shares Expires 2028-05-10 F2 · derivative.exercise_date: This option will become exercisable with respect to one quarter (1/4) of the shares underlying the option shall vest on March 12, 2019 (the "Initial Option Vesting Date")and one sixteenth (1/16) of the shares underlying the option shall vest on each successive quarterly anniversary of the Initial Option Vesting Date. Read SEC document |
| January 15, 2018 Filed Jan 22, 2018 14:25 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001144204-18-002949 · tv483653_4.xml · derivative · entry 1 Huertas Pedro · CIK 0001389517 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-15 F1 · derivative.exercise_date: The option vests over a four-year period commencing on January 15, 2018 in sixteen equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.